Vaccination against nonmutated neoantigens induced in recurrent and future tumors

Greta Garrido, Brett Schrand, Agata Levay, Ailem Rabasa, Anthony Ferrantella, Diane M. Da Silva, Francesca D'Eramo, Koen A. Marijt, Zhuoran Zhang, Deukwoo Kwon, Marcin Kortylewski, W. Martin Kast, Vikas Dudeja, Thorbald Van Hall, Eli Gilboa

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Vaccination of patients against neoantigens expressed in concurrent tumors, recurrent tumors, or tumors developing in individuals at risk of cancer is posing major challenges in terms of which antigens to target and is limited to patients expressing neoantigens in their tumors. Here, we describe a vaccination strategy against antigens that were induced in tumor cells by downregulation of the peptide transporter associated with antigen processing (TAP). Vaccination against TAP downregulation-induced antigens was more effective than vaccination against mutation-derived neoantigens, was devoid of measurable toxicity, and inhibited the growth of concurrent and future tumors in models of recurrence and premalignant disease. Human CD8+ T cells stimulated with TAPlow dendritic cells elicited a polyclonal T-cell response that recognized tumor cells with experimentally reduced TAP expression. Vaccination against TAP downregulation-induced antigens overcomes the main limitations of vaccinating against mostly unique tumorresident neoantigens and could represent a simpler vaccination strategy that will be applicable to most patients with cancer.

Original languageEnglish (US)
Pages (from-to)856-868
Number of pages13
JournalCancer Immunology Research
Issue number7
StatePublished - Jul 1 2020

ASJC Scopus subject areas

  • Immunology
  • Cancer Research


Dive into the research topics of 'Vaccination against nonmutated neoantigens induced in recurrent and future tumors'. Together they form a unique fingerprint.

Cite this